Armata Pharmaceuticals Q2 results: $15mln credit, positive Phase 1b/2a trial results.

• Armata Pharmaceuticals announces Q2 2025 results • Entered into a secured credit agreement with Innoviva for $15 million • Announced positive topline results from Phase 1b/2a diSArm trial for AP-SA02 • Focused on developing bacteriophage therapeutics for antibiotic-resistant infections • Credit agreement matures in 2029

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has announced its second-quarter 2025 financial results and several significant developments. The company reported a loss from operations of approximately $6.8 million, compared to a loss of approximately $11.9 million in the same period last year. Additionally, Armata entered into a secured credit agreement with Innoviva Strategic Opportunities LLC for a loan of $15.0 million, maturing on January 11, 2029 [2].

The company also announced positive topline results from the Phase 1b/2a diSArm trial for its AP-SA02 bacteriophage therapeutic candidate. The trial evaluated AP-SA02 in the treatment of complicated Staphylococcus aureus bacteremia and met all primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population [1]. Notably, the AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy, with no treatment-related serious adverse events observed [1].

Armata plans to hold an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the second half of this year to align on a superiority trial design for a Phase 3 pivotal trial in 2026 [2]. The company also received an additional $4.65 million of non-dilutive funding from the U.S. Department of Defense through the Medical Technology Enterprise Consortium (MTEC) [2].

Armata's Chief Executive Officer, Dr. Deborah Birx, stated, "These data are the first clear evidence in a randomized controlled trial of the effectiveness of phage in treating a serious systemic bacterial infection, with demonstrated efficacy regardless of antibiotic resistance patterns or site of infection. Findings from the diSArm study will inform the design of a larger definitive efficacy study to demonstrate superiority of AP-SA02 in treating complicated S. aureus bacteremia" [2].

The company continues to focus on developing bacteriophage therapeutics for antibiotic-resistant infections, with a state-of-the-art manufacturing platform that can achieve the high purity necessary for clinical success [2]. Armata's pipeline includes clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.

References:

[1] https://www.ainvest.com/news/stock/armp/
[2] https://investor.armatapharma.com/2025-08-12-Armata-Pharmaceuticals-Announces-Second-Quarter-2025-Results-and-Provides-Corporate-Update